Related Experiment Video
Updated: Mar 5, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Rivaroxaban Rebound Acute Coronary Event: A Post Marketing Experience
Ajay Agarwal1, Amish Patel1, Omar Mufti2
1Cardiology Division, Department of Internal Medicine at Wright State University Boonshoft School of Medicine, Dayton, OH, USA; Cardiology Department, Dayton VA Medical Center, Dayton, OH, USA.
Abstract:
We present a 65-year-old male who received rivaroxaban therapy prior to and after left knee replacement surgery. The patient developed generalized weakness soon after stopping rivaroxaban. An electrocardiogram showed acute infero-lateral ischemia and an echocardiogram reported an akinetic antero-apical wall segment, an apical clot and a reduced systolic function. A subsequent coronary angiogram revealed two-vessel coronary artery thrombosis. The case illustrates a temporal relationship of coronary thrombosis following rivaroxaban cessation.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Acute Coronary Syndrome III: Diagnostic Studies
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome V: Nursing Management
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

